Biotech Values

[swampboots]

<Even with GENR’s strengthened balance sheet from recent financings, GENR does not on its own have the resources to conduct “several key U.S. macular degeneration clinical trials” in 2004, as indicated in Dr. Levitt’s quote. Hence, a reasonable inference is that GENR believes a partnership deal will get done relatively soon.>

There is a detective exception imaginable (in dream state). If unofficial follow-up of previous subjects shouted stunning persistent effectiveness, GENR will keep whole pie with stock dilutions